UGT1A5 plays a crucial role in the glucuronidation process that affects the metabolism, efficacy, and side effects of certain medications, such as the statins atorvastatin and simvastatin, the anticonvulsant valproic acid, and the chemotherapeutic agent methotrexate. Variations in the activity of UGT1A5 can influence the clearance and toxicity of these drugs, impacting their therapeutic usefulness and safety.